148 related articles for article (PubMed ID: 35346500)
1. NDC80 Enhances Cisplatin-resistance in Triple-negative Breast Cancer.
Li J; Xu X; Peng X
Arch Med Res; 2022 Jun; 53(4):378-387. PubMed ID: 35346500
[TBL] [Abstract][Full Text] [Related]
2. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
3. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
4. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
7. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S
Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
10. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
13. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication.
Sheng X; Dai H; Du Y; Peng J; Sha R; Yang F; Zhou L; Lin Y; Xu S; Wu Y; Yin W; Lu J
J Exp Clin Cancer Res; 2021 Jun; 40(1):205. PubMed ID: 34162418
[TBL] [Abstract][Full Text] [Related]
14. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang S; Peng X; Li X; Yang P; Xie L; Li Y; Du C; Zhang G
Oncotarget; 2015 Jan; 6(2):1020-30. PubMed ID: 25544759
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
17. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
[TBL] [Abstract][Full Text] [Related]
18. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
19. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis.
Song X; Wang X; Chen X; Yu Z; Zhou Y
J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
